Robert Matts to Antineoplastic Agents
This is a "connection" page, showing publications Robert Matts has written about Antineoplastic Agents.
Connection Strength
0.678
-
Crystal structure of the middle and C-terminal domains of Hsp90a labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target. Acta Crystallogr D Struct Biol. 2022 May 01; 78(Pt 5):571-585.
Score: 0.134
-
Selective Inhibition of the Hsp90a Isoform. Angew Chem Int Ed Engl. 2021 05 03; 60(19):10547-10551.
Score: 0.124
-
Structure-guided design of an Hsp90ß N-terminal isoform-selective inhibitor. Nat Commun. 2018 01 30; 9(1):425.
Score: 0.100
-
Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay Drug Dev Technol. 2013 Oct; 11(8):478-88.
Score: 0.074
-
The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors. J Proteome Res. 2013 Aug 02; 12(8):3697-706.
Score: 0.073
-
Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. BMC Cancer. 2011 Oct 31; 11:468.
Score: 0.065
-
KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol. 2009 Dec; 76(6):1314-22.
Score: 0.056
-
Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. Curr Top Med Chem. 2009; 9(15):1462-78.
Score: 0.053